JelikaLite was awarded the National Science Foundation SBIR Phase II grant

JelikaLite was awarded the National Science Foundation SBIR Phase II grant

Products
Science
Autism
Company
Press & News

linkedin

Sign up for Early Access

Month: March 2021

March 16, 2021

Brain Scientific Announces Collaboration with JelikaLite in New Clinical Trial.

Learn More

Search for:

Recent Posts

We’re thrilled to share a significant achievement for JelikaLite. Our groundbreaking study, “Transcranial photobiomodulation for reducing symptoms of autism spectrum disorder and modulating brain electrophysiology in children aged 2–7: an open label study” has been published in Frontiers in Child and Adolescent Psychiatry 📚.
JelikaLite has been awarded a 2-year, $959,000 National Science Foundation (NSF) grant to develop a non-invasive therapeutic brain stimulation medical device to improve the communication, responsiveness, and social integration of autistic children. The project’s objectives are to finalize the current clinical prototype into a manufacturing-ready product and implement a platform for personalizing transcranial photobiomodulation (tPBM) treatment based on individual sensor -derived patient characteristics. Results could enrich scientific knowledge through personalization, monitoring, and data aggregation of neurological measures for further elucidating the mechanisms of autism and enhancing the efficacy of other therapies. Read more here https://lnkd.in/e23Yj74y.
We’re thrilled to share a significant achievement for JelikaLite. Our groundbreaking study, “Transcranial Photobiomodulation in Children Aged 2–6 Years: A Randomized Sham-Controlled Clinical Trial Assessing Safety, Efficacy, and Impact on Autism Spectrum Disorder Symptoms and Brain Electrophysiology,” has been published in Frontiers in Neurology 📚.
JelikaLite participated in Floreo VR’s inaugural virtual roundtable. A technology innovations such as Virtual Reality and wearables have begun to transform the delivery of behavioral therapy and developmental services for neurodiverse populations. Evidence demonstrates high levels of engagement among learners and the potential for improved outcomes. This panel discussed key trends, implications for therapy providers, what’s needed for further adoption, and the promise of these technologies.
JelikaLite is partnering with GoMo Health, for distribution of Cognilum treatment through national health care providers and Medicaid Managed Care Organizations throughout the U.S.. GoMo Health, a patient and consumer engagement company, works with providers, plans, employers, and pharma companies to improve engagement and patient outcomes across the world. GoMo Health has a growing Pediatric Autism program, making JelikaLite an ideal synergetic partner. On an annual basis, GoMo Health engages with over 8 million patients and members every day, focusing on serving economically disadvantaged communities worldwide.

Recent Comments

NATURAL MOUNJARO on JelikaLite presents results of the pivotal clinical trial at American Academy of Child & Adolescent Psychiatry.
NATURAL MOUNJARO RECIPE on BioWorld highlights JelikaLite’s breakthrough device designation status from the FDA in their featured article.
Salt trick recipe on JelikaLite presents results of the pivotal clinical trial at Rutgers University Center for Autism Research, Education, and Services (RUCARES)
Salt trick for man on JelikaLite’s StartEngine campaign is live! Since launching our campaign, our team has been blown away by the positive response we’ve received from our community. We are proud of our vision to revolutionalize the pediatric autism treatment and improve the lives of millions of families. We’re so excited to have you on this journey with us.
Salt trick for men on JelikaLite was awarded a National Science Foundation grant SBIR Phase 1: “EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism”. This new $256K grant will allow us to continue developing Cognilum, an intelligent non-invasive therapeutic personalized medical device, designed to be easily administered in the child’s home. This data-device modality could be disruptive in the Autism treatment standard of care.

Archives

January 2025
September 2024
May 2024
November 2023
May 2023
February 2023
January 2023
April 2022
January 2022
December 2021
October 2021
August 2021
June 2021
March 2021

Categories

Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

Company

Products
Science
Autism
Company
Press & News

Rules

Disclaimer
Privacy Policy

Social

linkedin

Copyright ©2025 jelikalite. All rights reserved.